MarketCap
Facebook
X
TelegramGW Pharmaceuticals plc Market Cap | GWPH
As of November 08, 2026 GW Pharmaceuticals plc has a market cap of $ 6.81 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap GW Pharmaceuticals plc
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 4.79 B | 41.9 B | 3.67 B | 2.68 B | 2.64 B | 1.62 B | 1.24 B | 387 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 41.9 B | 387 M | 7.37 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aridis Pharmaceuticals
ARDS
|
4.13 M | - | 17.91 % | $ 11.1 M |  USA |
 |
Seagen
SGEN
|
26.3 B | - | - | $ 42.2 B | USA |
 |
Baudax Bio
BXRX
|
779 K | - | 0.59 % | $ 63 K | USA |
 |
ChemoCentryx
CCXI
|
1.88 M | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
423 M | - | - | $ 789 M | USA |
 |
Zosano Pharma Corporation
ZSAN
|
52.7 M | - | 7.23 % | $ 2.72 M | USA |
 |
Oncternal Therapeutics
ONCT
|
27.3 M | - | -24.12 % | $ 1.56 M | USA |
 |
Iterum Therapeutics
ITRM
|
28 M | - | - | $ 591 K |  Irlanda |
 |
Spectrum Pharmaceuticals
SPPI
|
123 M | - | - | $ 189 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
13.5 M | - | - | $ 26.5 M | USA |
 |
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | USA |
 |
Concert Pharmaceuticals
CNCE
|
104 M | - | - | $ 401 M | USA |
 |
ImmunoGen
IMGN
|
1.02 B | - | - | $ 7.92 B | USA |
 |
Vascular Biogenics Ltd.
VBLT
|
528 K | - | -8.77 % | $ 12.4 M |  Israel |
 |
Histogen
HSTO
|
3.21 M | - | 31.6 % | $ 2.12 M | USA |
 |
Berkeley Lights
BLI
|
117 M | - | -7.31 % | $ 87 M | USA |
 |
Cidara Therapeutics
CDTX
|
148 M | - | - | $ 1.41 B | USA |
 |
Clovis Oncology
CLVS
|
262 M | - | -7.23 % | $ 13 M | USA |
 |
Kaleido Biosciences
KLDO
|
73.7 M | - | -3.69 % | $ 12.4 M | USA |
 |
VBI Vaccines
VBIV
|
9.65 M | - | -50.87 % | $ 1.09 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
551 M | - | - | $ 1.2 B | USA |
 |
Decibel Therapeutics
DBTX
|
102 M | - | - | $ 123 M | USA |
 |
NuCana plc
NCNA
|
85.4 B | $ 0.94 | 0.4 % | $ 10.6 B |  Britain |
 |
PhaseBio Pharmaceuticals
PHAS
|
115 M | - | 7.4 % | $ 6.29 M | USA |
 |
Provention Bio
PRVB
|
1.79 B | - | - | $ 2.37 B | USA |
 |
IVERIC bio
ISEE
|
2.97 B | - | - | $ 5.51 B | USA |
 |
Reata Pharmaceuticals
RETA
|
1.64 B | - | - | $ 6.29 B | USA |
 |
ObsEva SA
OBSV
|
156 M | - | -15.52 % | $ 10.5 M |  Schweiz |
 |
PolarityTE
PTE
|
4.32 M | - | -0.82 % | $ 1.78 M | USA |
 |
Kronos Bio
KRON
|
69.3 M | - | 1.49 % | $ 50.8 M | USA |
 |
Landos Biopharma
LABP
|
48.1 M | - | 0.58 % | $ 144 M | USA |
 |
Myovant Sciences Ltd.
MYOV
|
1.4 B | - | -0.04 % | $ 2.62 B | USA |
 |
Poseida Therapeutics
PSTX
|
306 M | - | - | $ 857 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
52.7 M | - | - | $ 231 M | USA |
 |
Trevena
TRVN
|
5.09 M | - | -46.58 % | $ 31.8 M | USA |
 |
Immunovant
IMVT
|
6.49 B | $ 30.5 | 7.43 % | $ 5.56 B | USA |
 |
Virpax Pharmaceuticals
VRPX
|
851 K | - | -45.12 % | $ 2.85 M | USA |
 |
Oncorus
ONCR
|
8.55 K | - | -8.54 % | $ 3.19 M | USA |
 |
Y-mAbs Therapeutics
YMAB
|
216 M | - | - | $ 382 M | USA |
 |
Navidea Biopharmaceuticals
NAVB
|
8.96 M | - | -2.99 % | $ 2.47 M | USA |
 |
InMed Pharmaceuticals
INM
|
5.45 M | $ 14.77 | 13.57 % | $ 61.5 M |  Canada |
 |
Stealth BioTherapeutics Corp
MITO
|
450 M | - | - | $ 23.9 M | USA |
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | USA |
 |
Satsuma Pharmaceuticals
STSA
|
27.2 M | - | -0.9 % | $ 36.5 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
291 M | $ 1.15 | 3.15 % | $ 98.1 M | USA |
 |
SpringWorks Therapeutics
SWTX
|
4.45 B | - | - | $ 3.48 B | USA |
 |
Metacrine
MTCR
|
13.5 M | - | - | $ 24.2 M | USA |
 |
Turning Point Therapeutics
TPTX
|
2.35 B | - | -0.13 % | $ 3.73 B | USA |
 |
Revolution Medicines
RVMD
|
19.6 B | $ 192.41 | 8.31 % | $ 36.6 B | USA |
 |
Infinity Pharmaceuticals
INFI
|
17 M | - | -46.98 % | $ 3.57 M | USA |